Jun 17 2014
Doctors are becoming wary of the appearance that drug makers' gifts can influence their prescription choices. Meanwhile, the federal government serves notice that it wants to find a way to preserve a regulation that would allow hospitals to get discounts on orphan drugs.
Texas Tribune: Trying To Limit Outside Influence Of Rx Drugs
As sales representatives for pharmaceutical companies brought doughnuts and lunch over the years to physicians at the 20 Kelsey-Seybold medical clinics in the Houston area, Patrick Carter worked to limit their presence. Carter, a family physician and managing director of care coordination for Kelsey-Seybold, said he wanted to remove the appearance that drug representatives influenced the decisions made by doctors when writing prescriptions. Since 2012, pharmaceutical representatives cannot stop by Kelsey-Seybold clinics or meet with its 370 doctors unless the physicians request an appointment for guidance in prescribing certain drugs (Ura, 6/16).
The Hill: HHS Vows To Fight For 'Orphan Drug' Rule
The Obama administration plans to fight for a rule that gives some medical facilities discounts on "orphan drugs" that are used to treat rare diseases. A circuit court in Washington, D.C., last month struck down a federal regulation on the drugs, leaving the Department of Health and Human Services (HHS) with a choice of either appealing or starting fresh with a new rule (Al-Faruque, 6/13).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|